ProQR Therapeutics (PRQR) Beginning Cash Balance (2013 - 2025)

ProQR Therapeutics (PRQR) has reported Beginning Cash Balance for 13 consecutive years, with $136.3 million the latest figure, recorded in Q3 2025.

• Quarterly Beginning Cash Balance rose 51.66% year-over-year to $136.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $493.7 million (up 5.26% YoY) and the FY2021 annual result came in at $86.3 million, down 32.26% from the prior year.
• Beginning Cash Balance declined to $136.3 million in Q3 2025 per PRQR's latest filing, from $170.0 million in the prior quarter.
• Over the last five years, Beginning Cash Balance for PRQR reached as high as $213.4 million in Q1 2022 and fell as low as $77.2 million in Q2 2021.
• A 5-year average of $141.6 million and a median of $146.3 million in 2023 frame the typical range for Beginning Cash Balance.
• Annual changes were most pronounced in 2021 — Beginning Cash Balance surged 67642.74% — and 2023, when it plunged 49.46%.
• Year by year, Beginning Cash Balance stood at $177.7 million in 2021, then climbed by 0.17% to $178.0 million in 2022, then retreated by 17.8% to $146.3 million in 2023, then slumped by 38.57% to $89.9 million in 2024, then jumped by 51.66% to $136.3 million in 2025.
• According to Business Quant data, Beginning Cash Balance over the past three periods registered $136.3 million, $170.0 million, and $89.9 million for Q3 2025, Q1 2025, and Q3 2024 respectively.